JP5959506B2 - 妊娠合併症を治療するための体外デバイスおよび方法 - Google Patents

妊娠合併症を治療するための体外デバイスおよび方法 Download PDF

Info

Publication number
JP5959506B2
JP5959506B2 JP2013510331A JP2013510331A JP5959506B2 JP 5959506 B2 JP5959506 B2 JP 5959506B2 JP 2013510331 A JP2013510331 A JP 2013510331A JP 2013510331 A JP2013510331 A JP 2013510331A JP 5959506 B2 JP5959506 B2 JP 5959506B2
Authority
JP
Japan
Prior art keywords
sflt
pregnancy
subject
level
apheresis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013510331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532129A (ja
JP2013532129A5 (https=
Inventor
カルマンチ，アナンス，エス．
Original Assignee
ベス イスラエル デアコネス メディカル センター インコーポレイテッド
ベス イスラエル デアコネス メディカル センター インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベス イスラエル デアコネス メディカル センター インコーポレイテッド, ベス イスラエル デアコネス メディカル センター インコーポレイテッド filed Critical ベス イスラエル デアコネス メディカル センター インコーポレイテッド
Publication of JP2013532129A publication Critical patent/JP2013532129A/ja
Publication of JP2013532129A5 publication Critical patent/JP2013532129A5/ja
Application granted granted Critical
Publication of JP5959506B2 publication Critical patent/JP5959506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013510331A 2010-05-14 2011-05-13 妊娠合併症を治療するための体外デバイスおよび方法 Active JP5959506B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33482410P 2010-05-14 2010-05-14
US61/334,824 2010-05-14
US34621610P 2010-05-19 2010-05-19
US61/346,216 2010-05-19
PCT/US2011/036409 WO2011143538A1 (en) 2010-05-14 2011-05-13 Extracorporeal devices and methods of treating complications of pregnancy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016030745A Division JP2016147065A (ja) 2010-05-14 2016-02-22 妊娠合併症を治療するための体外デバイスおよび方法

Publications (3)

Publication Number Publication Date
JP2013532129A JP2013532129A (ja) 2013-08-15
JP2013532129A5 JP2013532129A5 (https=) 2014-05-15
JP5959506B2 true JP5959506B2 (ja) 2016-08-02

Family

ID=44911968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013510331A Active JP5959506B2 (ja) 2010-05-14 2011-05-13 妊娠合併症を治療するための体外デバイスおよび方法
JP2016030745A Pending JP2016147065A (ja) 2010-05-14 2016-02-22 妊娠合併症を治療するための体外デバイスおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016030745A Pending JP2016147065A (ja) 2010-05-14 2016-02-22 妊娠合併症を治療するための体外デバイスおよび方法

Country Status (7)

Country Link
US (2) US8969322B2 (https=)
EP (3) EP3248946B1 (https=)
JP (2) JP5959506B2 (https=)
CN (1) CN102884006B (https=)
AU (1) AU2011252954B2 (https=)
CA (1) CA2799227C (https=)
WO (1) WO2011143538A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925211B2 (en) 2010-05-14 2018-03-27 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8979787B2 (en) * 2011-01-20 2015-03-17 Henry John Smith Treatment of pre-eclampsia using targeted apheresis
MX2015010174A (es) * 2013-02-08 2016-03-31 Univ Iowa Res Found Herramientas de diagnostico para predecir la presentacion de preeclampsia.
KR20160102440A (ko) * 2013-12-27 2016-08-30 엘리아스 세라퓨틱스 인코포레이티드 혈장 분리 반출 장치
EP3097422B1 (en) 2014-01-24 2018-07-11 Roche Diagnostics GmbH Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
US11383015B2 (en) * 2016-01-11 2022-07-12 Fenwal, Inc. System and method for plasma purification prior to mononuclear cell collection
CN108883193A (zh) 2016-03-31 2018-11-23 伊穆特丽克斯治疗股份有限公司 先兆子痫和有关障碍的体外治疗方法
WO2019026870A1 (ja) * 2017-08-01 2019-02-07 学校法人学文館 ｓＦｌｔ－１（可溶型血管内皮増殖因子受容体－１）の新規測定法
US20200264188A1 (en) * 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2020061590A1 (en) * 2018-09-21 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for evaluation of gestational progress and preterm abortion for clinical intervention and applications thereof
EP3669888B1 (en) 2018-12-20 2025-09-24 Gambro Lundia AB Extracorporeal devices for methods for treating diseases associated with anti-neutrophil cytoplasmic antibodies
JP7526737B2 (ja) 2019-03-06 2024-08-01 ガンブロ ルンディア アクティエボラーグ アルカリホスファターゼを含む血液処理装置
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery
WO2024232421A1 (ja) 2023-05-11 2024-11-14 タグシクス・バイオ株式会社 可溶性ｆｌｔ－１に選択的に結合するｄｎａアプタマーおよびそのｄｎａアプタマーが固定化された担体
WO2025240713A1 (en) * 2024-05-17 2025-11-20 Aslam Shakil Method for treating pre-eclampsia with stationary phase heparin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US4994161A (en) * 1989-02-02 1991-02-19 University Of New Hampshire Apparatus and method for macromolecular charge determination
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
AU4410296A (en) 1994-11-29 1996-06-19 Duke University Diagnosis of and therapy for hereditary haemorrhagic telangiectasia
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
DE10117043A1 (de) 2001-04-05 2002-11-07 Gerhard Puetz Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
ES2534926T3 (es) 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US20060067931A1 (en) 2004-09-25 2006-03-30 Hazel Lum Receptor for lysophosphatidylcholine in vascular endothelial cells and use thereof
EP1839056B1 (en) * 2004-12-21 2011-08-03 Yale University Diagnosis of preeclampsia
US20060153835A1 (en) * 2005-01-12 2006-07-13 Smith Henry J Treatment of pre-eclampsia in pregnant women using targeted apheresis
MX2008015197A (es) 2006-05-31 2009-06-23 Beth Israel Hospital Metodos de diagnosticar y tratar las complicaciones del embrazo.
US20090286271A1 (en) 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
PH12012500781A1 (en) * 2009-11-09 2015-03-04 Zeiss Carl Vision Int Gmbh Ophthalmic lens element
AU2011252954B2 (en) 2010-05-14 2015-04-16 Beth Israel Deaconess Medical Center Extracorporeal devices and methods of treating complications of pregnancy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925211B2 (en) 2010-05-14 2018-03-27 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy

Also Published As

Publication number Publication date
EP3248946A1 (en) 2017-11-29
EP2706041B1 (en) 2018-10-03
CA2799227C (en) 2020-06-16
CN102884006B (zh) 2016-02-17
EP2569253A4 (en) 2013-10-02
US20110280825A1 (en) 2011-11-17
WO2011143538A1 (en) 2011-11-17
CN102884006A (zh) 2013-01-16
EP2706041A1 (en) 2014-03-12
JP2016147065A (ja) 2016-08-18
US8969322B2 (en) 2015-03-03
JP2013532129A (ja) 2013-08-15
EP2569253A1 (en) 2013-03-20
CA2799227A1 (en) 2011-11-17
US9925211B2 (en) 2018-03-27
US20150132250A1 (en) 2015-05-14
AU2011252954A1 (en) 2012-11-22
EP3248946B1 (en) 2021-02-24
AU2011252954B2 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
JP5959506B2 (ja) 妊娠合併症を治療するための体外デバイスおよび方法
Feld et al. Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment
JP2013532129A5 (https=)
JP6169495B2 (ja) 妊娠関連高血圧性障害を治療または予防するための方法およびシステム
EP2622354A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Kishi et al. Pentoxifylline attenuates reperfusion injury in skeletal muscle after partial ischemia
Awad et al. Intracellular and extracellular expression of the major inducible 70kDa heat shock protein in experimental ischemia-reperfusion injury of the spinal cord
Klinkmann et al. Therapeutic apheresis in sepsis
WO2012093681A1 (ja) 敗血症治療薬を投与する患者を選択する方法
HK1189566A (en) Extracorporeal devices and methods of treating complications of pregnancy
Antunes et al. The use of ultrafiltration for inflammatory mediators removal during cardiopulmonary bypass in coronary artery bypass graf surgery
Sudnik et al. The role of selectins in alopecia areata
Končeková et al. Effectiveness of remote ischaemic conditioning is not affected by hyper-inflammation in a rat model of stroke
JP2002533679A (ja) アルカリホスファターゼのｌｐｓ−結合部分を使用する敗血症の診断
JP2825283B2 (ja) 血管障害判定法
Guo et al. Calcitriol ameliorates the progression of hepatic fibrosis through autophagy-related gene 16-like 1-mediated autophagy
Jiang et al. The Effect of Heparin-Grafted Chitosan-Cellulose Composite Microspheres on the Removal of Endotoxins and Circulating Histones in a Septic Rabbit Model: An In Vivo Study
RU2196589C2 (ru) Способ индукции рассасывания образовавшихся рубцов или фиброзных образований в кровеносных сосудах или в сосудистой сети млекопитающего
HK40113884A (zh) 肾脏疾病的治疗
CN116530469A (zh) 腹主动脉瘤动物模型的制备方法与应用
Padigala et al. 75 EFFECTS OF RENAL ARTERY STENTING ON KIDNEY FUNCTION AND BLOOD PRESSURE IN PATIENTS WITH ATHEROSCLEROTIC RENAL ARTERY DISEASE: OUR EXPERIENCE.
Singleton et al. 77 NOVEL MECHANISM OF PROSTAGLANDIN E2-MEDIATED ENDOTHELIAL CELL BARRIER ENHANCEMENT: ROLE OF EPCR, S1P1 RECEPTOR, EPAC, RAP1, AF-6, AND PROFILIN.
Simpson 76 A RARE CASE OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS POSITIVE FOR BOTH ANTIGLOMERULAR BASEMENT MEMBRANE ANTIBODY AND PERINUCLEAR ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY.
CA2625888A1 (en) Method of treating acute renal failure with thrombomodulin variant
Zhao et al. 79 LYSOPHOSPHATIDIC ACID INDUCES INTERLEUKIN-13 RECEPTOR a2 EXPRESSION AND SECRETION AND DOWN-REGULATES INTERLEUKIN-13 SIGNALING IN HUMAN BRONCHIAL EPITHELIAL PRIMARY CELLS.

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20130729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160222

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160621

R150 Certificate of patent or registration of utility model

Ref document number: 5959506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250